Show simple item record

dc.contributor.authorSimiyu, DE
dc.contributor.authorOkello, C
dc.contributor.authorNyakundi, EG
dc.contributor.authorTawakal, AH
dc.date.accessioned2013-06-22T12:05:52Z
dc.date.available2013-06-22T12:05:52Z
dc.date.issued2006
dc.identifier.citationEast Afr Med J. 2006 Jun;83(6):337-340en
dc.identifier.urihttp://www.ajol.info/index.php/eamj/article/view/9442
dc.identifier.urihttp://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/38224
dc.description.abstractPersistent pulmonary hypertension of the newborn (PPHN) was described in 1969 by Gersomy and co-workers as persistent foetal circulation. Supra - systemic pulmonary artery pressures result in right to left shunting of blood through the ductus arteriosus and/or foramen ovale. This results from failure of the normal adaptation to extra uterine life of the foetal heart/lung system. The incidence is estimated at about 0.1-0.2% of live born infants, majority being term or post term. There is no race or gender related predisposition. Management was always difficult before the advent of nitric oxide (and now sildenafil). We report two newborn infants born at The Mater Hospital with perinatal asphyxia resulting in persistent pulmonary hypertension that were successfully managed with sildenafilen
dc.language.isoenen
dc.publisherKMAen
dc.titleSildenafil in management of persistent pulmonary hypertension of the newborn: report of two casesen
dc.typeArticleen
local.publisherDepartment of Pediatrics, University of Nairobi,en
local.publisherDepartment Of Pharmaceutics And Pharmacy Practice.en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record